Loading...

Jacobio Pharmaceuticals Group Co., Ltd.

1167.HKHKSE
Healthcare
Biotechnology
HK$4.34
HK$0.11(2.60%)

Jacobio Pharmaceuticals Group Co., Ltd. 1167.HK Peers

See (1167.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
1167.HKHK$4.34+2.60%3.4B-19.73-HK$0.22N/A
1801.HKHK$78.40+1.36%129.5B-1306.67-HK$0.06N/A
2269.HKHK$25.65+1.99%104.4B30.18HK$0.85N/A
1177.HKHK$5.26-0.75%94.1B47.82HK$0.11+1.33%
9926.HKHK$91.95-0.59%82.4B-141.46-HK$0.65N/A
1530.HKHK$23.65+4.19%55.8B25.43HK$0.93+1.06%
3759.HKHK$16.58+4.02%44.9B14.42HK$1.15N/A
9995.HKHK$54.45-1.98%37.2B-18.27-HK$2.98N/A
1877.HKHK$20.75-0.72%33.9B-14.61-HK$1.42N/A
6821.HKHK$78.70+10.07%32.8B24.16HK$3.08+1.53%
Showing 1 to 10 of 56 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

1167.HK vs 1801.HK Comparison

1167.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1167.HK stands at 3.4B. In comparison, 1801.HK has a market cap of 129.5B. Regarding current trading prices, 1167.HK is priced at HK$4.34, while 1801.HK trades at HK$78.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1167.HK currently has a P/E ratio of -19.73, whereas 1801.HK's P/E ratio is -1306.67. In terms of profitability, 1167.HK's ROE is -0.17%, compared to 1801.HK's ROE of -0.01%. Regarding short-term risk, 1167.HK is less volatile compared to 1801.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1167.HK.

Stock Price Comparison

Loading...

Frequently Asked Questions

;